DDInter1956 DDInter969
A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approval on 25 March 2011.
Zalcitabine {u} (Compound) resembles {v} (Compound) Didanosine
Didanosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ipilimumab
Zalcitabine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Budesonide
Budesonide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ipilimumab
Zalcitabine {u} (Compound) resembles {v} (Compound) Didanosine
Didanosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Interferon beta-1a
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ipilimumab
Zalcitabine {u} (Compound) upregulates {v} (Gene) GPC1
GPC1 {u} (Gene) is upregulated by {v} (Compound) Budesonide
Budesonide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ipilimumab
Zalcitabine {u} (Compound) downregulates {v} (Gene) HSPA1A
HSPA1A {u} (Gene) is downregulated by {v} (Compound) Budesonide
Budesonide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ipilimumab
Zalcitabine {u} (Compound) downregulates {v} (Gene) HSPA1A
HSPA1A {u} (Gene) is upregulated by {v} (Compound) Pitavastatin
Pitavastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ipilimumab
Zalcitabine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Cabazitaxel
Cabazitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ipilimumab
Zalcitabine {u} (Compound) causes {v} (Side Effect) Pain
Pain {u} (Side Effect) is caused by {v} (Compound) Budesonide
Budesonide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ipilimumab
Zalcitabine {u} (Compound) downregulates {v} (Gene) HSPA1A
HSPA1A {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ipilimumab
Zalcitabine {u} (Compound) upregulates {v} (Gene) GPC1
GPC1 {u} (Gene) is downregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ipilimumab
Zalcitabine (Compound) resembles Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Zalcitabine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Zalcitabine (Compound) resembles Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Zalcitabine (Compound) upregulates GPC1 (Gene) and GPC1 (Gene) is upregulated by Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Zalcitabine (Compound) downregulates HSPA1A (Gene) and HSPA1A (Gene) is downregulated by Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Zalcitabine (Compound) downregulates HSPA1A (Gene) and HSPA1A (Gene) is upregulated by Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Zalcitabine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cabazitaxel (Compound) and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Zalcitabine (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Zalcitabine (Compound) downregulates HSPA1A (Gene) and HSPA1A (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Zalcitabine (Compound) upregulates GPC1 (Gene) and GPC1 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab